Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will host an overseas Non-Deal Roadshow (NDR) in Hong Kong, sponsored by CLSA, targeting major foreign institutional investors to present its platform technologies and pipeline status/plans.
📊 [Key Disclosure Details & Major Figures Summary]
- Event Name: Non-Deal Roadshow (NDR) for Major Overseas Institutional Investors
- Date & Time: October 16, 2025 – October 17, 2025 (09:00 – 18:00, Local Time)
- Location: Hong Kong
- Target Audience: Major overseas institutional investors
- Purpose: To enhance corporate recognition through introductions of company overview, core technologies, and R&D pipelines
- Method: Non-Deal Roadshow (NDR) format (Presentation & Q&A)
- Key Details: Presentation of ALTEOGEN’s platform technologies, pipeline status, and future plans; Q&A
- Sponsoring Institution: CLSA
- Confirmation Date: October 10, 2025
- Contact Department: IR Team (Tel: +82-42-384-8777)
- IR Material Publication: Scheduled for publication on October 16, 2025, on the KRX KIND system website (http://kind.krx.co.kr)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Platform Technologies and Pipeline Status via Published IR Materials
The company plans to publish its IR presentation materials on the KRX KIND system on October 16, 2025, for this NDR event. Reviewing the official presentation materials provided to major foreign institutional investors in Hong Kong is essential because it allows investors to accurately understand the progress of core platform technologies and pipeline strategic directions. Detailed contents can be cross-checked in the official IR presentation materials published on the KRX KIND system website.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
